^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    HelioLiver Dx test

    Company:
    Helio Genomics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    21d
    Helio Genomics to Make HelioLiver™ Cancer Test Accessible to Quest Diagnostics’ Providers (HelioHealth Press Release)
    ''Helio Genomics...today announced an agreement with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, to make HelioLiver™, Helio Genomics’ innovative blood-based early detection test for Hepatocellular Carcinoma (HCC), widely available to physicians and patients through Quest’s extensive U.S. network. ''
    Clinical
    |
    HelioLiver Dx test
    over1year
    Helio Genomics presented CLiMB trial data evaluating HelioLiver for detecting early-stage HCC and methylation model score for assessing prognosis at AASLD and Virtual KOL event, featuring chief medical advisor Dr. Richard Van Etten, MD, PhD (GlobeNewswire)
    "Helio Genomics...presented and discussed recent CLiMB trial data evaluating HelioLiver, a multi-analyte blood test, in patients with hepatocellular carcinoma (HCC), as well as its cell-free DNA (cfDNA) methylation biomarkers for assessing prognosis and treatment response at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting held November 18, 2024 and virtual KOL event held November 25, 2024. Both events featured Helio’s Chief Medical Advisor, Dr. Richard Van Etten, MD, PhD."
    Clinical data
    |
    HelioLiver Dx test